RE:Combo treatment for NASH and it’s potentials..So much science so little deals. If this CEO can't monetize Nash after so many years, well maybe it's time to consider the fact that something is not so much appealing to the partners. My guess is the patents that are weak. Anyway it's there until they take a write down with it. In the mean time there are echos of cognitive data from Greenspoon on the way. Maybe they relaunch the whole cognitive story about Egrifta and have another story to talk about for the next 24 months.